The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Eli Lilly & Co. shares plunge 12.5% this month, worst since 2009, due to disappointing earnings and lowered guidance. The ...

Tirzepatide is a long-acting dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist.

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

Management at Eli Lilly has expressed strong confidence in the growing demand for their obesity franchise and a robust pipeline of new products. The company is anticipating significant benefits from ...

As millions patients struggled to fill their prescriptions for the new weight loss drugs, many have turned to compounded copies.

(HealthDay News) — For patients with obesity and prediabetes, 3 years of tirzepatide yields substantial and sustained weight reduction and a reduced risk for progression to type 2 diabetes, according ...

The FDA rejected an application from Astellas seeking to change the prescribing label for its eye drug Izervay to allow less ...

The American Heart Association held its annual Scientific Sessions Nov. 16-18 in Chicago, where healthcare organizations and industry leaders presented the latest research on cardiovascular health.

Drug manufacturers have increased their production, and some such as Novo Nordisk have asked the FDA to ban further production of compounded versions of their drugs. If that happens, Lavin says many ...

For tirzepatide, the clinical name for Eli Lilly’s Mounjaro and Zepbound, the number dropped to 25%. Pemvidutide’s latest ...

"Over 50% of my patients on semaglutide and tirzepatide have remarkably less desire to drink alcohol." Decotiis also ...